Zobrazeno 1 - 10
of 413
pro vyhledávání: '"Glucagon-like peptide 1 receptor agonists"'
Autor:
Graciela Zambrano-Galván, Ángel González-Romero, Miguel A. Reyes-Romero, Abelardo Camacho-Luis
Publikováno v:
Revista Mexicana de Endocrinología, Metabolismo y Nutrición, Vol 11, Iss 4 (2024)
Intestinal incretins, glucagon-like peptide 1 (GLP-1), and gastric insulinotropic peptide, which are released after food ingestion, have glucoregulatory effects, which is why, in recent years, pharmacological agents with an impact similar to incretin
Externí odkaz:
https://doaj.org/article/c25ef5cbde2849b68d042d5b5a2c69bd
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 16, Iss 1, Pp 1-12 (2024)
Abstract Objective To assess the effects of finerenone and glucagon-like peptide 1 receptor agonists (GLP1-RA) on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus (T2DM), and the relative cardiovascular benefits in patients
Externí odkaz:
https://doaj.org/article/37b7e50e5c504bf0b87895098b7d409c
Autor:
Frederick Berro Rivera, Linnaeus Louisse A. Cruz, John Vincent Magalong, Jade Monica Marie J. Ruyeras, John Paul Aparece, Nathan Ross B. Bantayan, Kyla Lara-Breitinger, Martha Gulati
Publikováno v:
American Journal of Preventive Cardiology, Vol 18, Iss , Pp 100679- (2024)
Background: Multiple cardiovascular outcomes trials (CVOTs) have shown the efficacy of GLP-1RAs in reducing major adverse cardiovascular events (MACEs) for high-risk patients. However, some CVOTs failed to demonstrate cardiovascular benefits. Objecti
Externí odkaz:
https://doaj.org/article/ddaeeef737334d64a0255d15e73a22cc
Autor:
Omar A. Alshaya, Ghazwa B. Korayem, Munirah Alghwainm, Wed Alyami, Albandari Alotaibi, Majed S. Alyami, Omar A. Almohammed
Publikováno v:
Saudi Pharmaceutical Journal, Vol 32, Iss 5, Pp 102054- (2024)
Background: Atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), chronic kidney disease (CKD), and obesity are associated with increased morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Nonetheless, their preva
Externí odkaz:
https://doaj.org/article/8d6b18b7d7c449c6995037f0ecdd896f
GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionLymphedema is a major public health issue for many women undergoing breast cancer treatment. Although weight loss has been reported to be beneficial in the treatment of lymphedema, no studies to date have examined the use of GLP-1RAs for
Externí odkaz:
https://doaj.org/article/29085305ba3a40c5acb30bc52991b79a
Autor:
Fatima H, Rangwala HS, Mustafa MS, Shafique MA, Abbas SR, Rizwan A, Fadlalla Ahmed TK, Arshad A
Publikováno v:
Diabetes, Metabolic Syndrome and Obesity, Vol Volume 16, Pp 3567-3578 (2023)
Hareer Fatima,1 Hussain Sohail Rangwala,1 Muhammad Saqlain Mustafa,1 Muhammad Ashir Shafique,1 Syed Raza Abbas,2 Azra Rizwan,3 Tagwa Kalool Fadlalla Ahmed,4 Ainan Arshad3 1Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan; 2D
Externí odkaz:
https://doaj.org/article/840dc750a61c435a94d6fe73f50a2e38
Autor:
Yoshimi Muta, Kazuo Kobayashi, Masao Toyoda, Atsuhito Tone, Daisuke Suzuki, Daisuke Tsuriya, Hideo Machimura, Hidetoshi Shimura, Hiroshi Takeda, Hisashi Yokomizo, Kei Takeshita, Keiichi Chin, Keizo Kanasaki, Kouichi Tamura, Masaaki Miyauchi, Masuo Saburi, Miwa Morita, Miwako Yomota, Moritsugu Kimura, Nobuo Hatori, Shinichi Nakajima, Shun Ito, Shunichiro Tsukamoto, Takashi Murata, Takaya Matsushita, Takayuki Furuki, Takuya Hashimoto, Tomoya Umezono, Yuichi Takashi, Daiji Kawanami
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Accumulating evidence has demonstrated that both SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP1Ra) have protective effects in patients with diabetic kidney disease. Combination therapy with SGLT2i and GLP1Ra is commonly used in patients
Externí odkaz:
https://doaj.org/article/e387d4d5ba7242e08853f9abf1debf8d
Autor:
M. B. Antsiferov, G. R. Galstyan, T. Yu. Demidova, A. V. Zilov, T. N. Markova, А. M. Mkrtumyan, N. A. Petunina, I. S. Khalimov, M. S. Shamkhalova, M. V. Shestakova
Publikováno v:
Сахарный диабет, Vol 26, Iss 2, Pp 211-214 (2023)
Type 2 diabetes is characterized by increasing incidence and prevalence all-over the world. Current therapeutic management of type 2 diabetes is complex and is based not only on glycemic control, but also on cardiovascular and renal risks reduction.
Externí odkaz:
https://doaj.org/article/d859b678f86d4281a70004385fe60c28
Publikováno v:
Biomedicines, Vol 12, Iss 5, p 1102 (2024)
Type 2 diabetes mellitus (T2DM) is a significant risk factor for stroke. Nevertheless, the evidence supporting stringent glycemic control to reduce macrovascular complications, particularly stroke, is not as clear as for microvascular complications.
Externí odkaz:
https://doaj.org/article/09f208d55dc34b4ea838243b56369a48
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Alzheimer’s disease (AD) is a degenerative disease of the nervous system. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a drug used to treat type 2 diabetes, have been shown to have neuroprotective effects. This systematic review and meta-
Externí odkaz:
https://doaj.org/article/9853c1138ac649a987e96bec10d29721